论文部分内容阅读
目的探讨OHLF3方案联合贝伐单抗治疗晚期胃癌的临床疗效及安全性。方法将2013年1月至2014年12月收治的96例晚期胃癌患者随机分成对照组与观察组,每组各48例,其中对照组按照OHLF3方案进行治疗,观察组在对照组治疗的基础上加用贝伐单抗,两组疗程均为3周,治疗2、4个疗程,根据改良版实体瘤疗效评价标准(mRCIST)评价肿瘤反应,观察并评价两组患者的临床疗效、糖类抗原19-9(CA19-9)、糖类抗原242(CA242)及癌胚抗原(CEA)水平变化及不良反应发生情况。结果观察组患者治疗2、4个疗程后的临床收益率(CBR)分别为81.3%、85.4%,均显著高于对照组的68.8%、72.9%,差异有统计学意义(P均<0.05);治疗后两组各血清肿瘤标志物水平均显著低于治疗前,且观察组各肿瘤标志物水平改善程度均显著优于对照组,差异均有统计学意义(P均<0.05);两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论 OHLF3方案联合贝伐单抗治疗晚期胃癌疗效显著,安全可靠。
Objective To investigate the clinical efficacy and safety of OHLF3 combined with bevacizumab in the treatment of advanced gastric cancer. Methods Ninety-six patients with advanced gastric cancer who were admitted from January 2013 to December 2014 were randomly divided into control group and observation group, with 48 cases in each group. The control group was treated according to OHLF3 regimen. The observation group was treated on the basis of the control group Plus bevacizumab, the two courses of treatment were 3 weeks, 2 and 4 courses of treatment, according to modified solid tumors evaluation criteria (mRCIST) evaluation of tumor response to observe and evaluate the clinical efficacy of two groups of patients, carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242) and carcinoembryonic antigen (CEA) levels and adverse reactions. Results The clinical response rate (CBR) of observation group after treatment was 81.3% and 85.4% respectively, which were significantly higher than that of the control group (68.8% and 72.9% respectively) (P <0.05) ; After treatment, the levels of serum tumor markers in both groups were significantly lower than before treatment, and the levels of tumor markers in the observation group were significantly better than those in the control group (all P <0.05); two groups The total incidence of adverse reactions was no significant difference (P> 0.05). Conclusion OHLF3 combined with bevacizumab is effective and safe in the treatment of advanced gastric cancer.